Focused On-demand Library for STAGA complex 65 subunit gamma

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O94864

UPID:

ST65G_HUMAN

Alternative names:

Adenocarcinoma antigen ART1; SPTF-associated factor 65 gamma; Suppressor of Ty 7-like

Alternative UPACC:

O94864; B4E3W3; Q6IB21; Q9H2T6

Background:

The STAGA complex 65 subunit gamma, also known by its alternative names Adenocarcinoma antigen ART1, SPTF-associated factor 65 gamma, and Suppressor of Ty 7-like, plays a crucial role in the regulation of gene expression through its involvement in the STAGA complex. This protein's multifaceted role in biological systems makes it an intriguing subject for scientific inquiry, particularly in understanding its contribution to chromatin modification and transcriptional regulation.

Therapeutic significance:

Understanding the role of STAGA complex 65 subunit gamma could open doors to potential therapeutic strategies. Its involvement in critical cellular processes underscores the importance of further research to elucidate its functions and implications in disease mechanisms.